Navigation Links
Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
Date:1/20/2009

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, selectively delivers SN-38 to human colon carcinoma in animal models as an effective new therapy.

SN-38 is the active metabolite of irinotecan, a chemotherapeutic agent approved by the FDA for the treatment of colorectal, lung, and other cancers. Due to its toxicity and poor solubility, SN-38 cannot be administered systemically to cancer patients. The Company has previously reported that by conjugating SN-38 to antibodies, the powerful cancer drug can be delivered selectively to tumors, thereby increasing the amount reaching the tumors and minimizing damage to normal tissues and organs. (Please refer to http://www.immunomedics.com/news_pdf/2008_PDF/PR03202008.pdf).

In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer. Labetuzumab is a non-internalizing humanized antibody that binds to the carcinoembryonic antigen (CEACAM5) expressed by many solid cancers. The Company has conducted clinical trials with the naked and radiolabeled antibody in patients with colorectal, breast and pancreas cancers.

In a lung metastatic model of colon carcinoma, therapy with labetuzumab-SN-38 conjugate increased median survival time (MST) 1.9- to 3.4-fold compared to various controls, with 20% of animals alive at the end of the study. In another colon cancer model, MST for the immunoconjugate treatment group in
'/>"/>

SOURCE Immunomedics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
2. Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinsons Disease Drug KW-6002 (Istradefylline)
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
5. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
6. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015  Unilife Corporation (NASDAQ: UNIS ... of injectable drug delivery systems, announced today that its ... June 30, 2015. This amendment removed a covenant that ... cash receipts from customers during the six months ended ... any of the terms of the debt agreement as ...
(Date:7/1/2015)... July 1, 2015 Qiming Venture Partners, today ... Managing Partner effective immediately. William has been ... and participated in many Qiming healthcare deals, and assisted ... Chinese market. Qiming, s success in healthcare is not ... distinguished himself with his outstanding advocacy and service mentality ...
(Date:7/1/2015)... 2015 According to a new ... Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), ... Global Forecast to 2020", published by MarketsandMarkets, the Transfection ... $957.9 Million by 2020 with a CAGR of 7.2% ... market T ables and 33 F ...
Breaking Medicine Technology:Unilife and OrbiMed Amend Debt Financing Agreement 2Unilife and OrbiMed Amend Debt Financing Agreement 3Qiming Announces the Promotion of William Hu to Managing Partner 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
... Pharmaceuticals Inc. (Nasdaq: CPIX ) announced today that it will report first ... 2010 .  A conference call and live Internet webcast will be held on ... to discuss the results. , , ... in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international ...
... Israel , May 3, 2010 , , ... The Company is Developing an Artificial Sphincter (the AOS-C1000) to,Provide Bowel Control and Prevent Clinical Complications for ... Stimatix GI, located in the Misgav Venture Accelerator, ... with a new means of bowel,control. , , , ...
Cached Medicine Technology:Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010 2Stimatix GI Reports Encouraging Interim Results 2
(Date:7/1/2015)... ... 2015 , ... As if mood swings, cramps and child labor weren’t enough ... leg pain. Northeast Houston Vein Center is offering tips on the treatment options for ... is underdiagnosed and often overlooked. Many women experience the tiredness, achiness, restless legs, cramps ...
(Date:7/1/2015)... ... ... Trevor L. Williams, DMD holds a Bachelor of Science degree in Biomedical Sciences ... in Microbiology. He graduated from the University of Florida College of Dentistry in 2015 ... and the Academy of General Dentistry. Dr. Williams was born in Tampa and is ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... of IBM software products, announced today that it has received trademark protection for ... display and detailed analysis of data from multiple sources providing an environment where ...
(Date:7/1/2015)... ... 2015 , ... A Priority Setting Partnership put in place ... they hope will guide future mesothelioma research. Surviving Mesothelioma has just posted an ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer the mesothelioma ...
(Date:7/1/2015)... York (PRWEB) , ... July 01, 2015 , ... Author Francesca Camp wasn’t ... fell into her lap, so too did her support of the practice; a terrible car ... , In her new book, “Do I Need It ? (And What if I ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... the battle against malignant brain tumors, dual implantation ... showed promising results in a study led by ... of Cincinnati (UC) and University Hospital. , The ... Journal of Neurosurgery, revealed that patients treated with ...
... Gornick LLP, Bailey Perrin Bailey LLP and Weitz &, ... United, States District Court for the Eastern District of New York ... Co., Inc. and Schering-Plough Corporation., ... the law,firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, ...
... Five Such Cases Known Worldwide, NEW HYDE PARK, N.Y., ... physicians at LIJ Medical,Center, 25-year-old Stacey Gayle can now look ... radio. At a news conference today, Ms.,Gayle and her doctors ... robbed her of her health, but of the very important,gift ...
... Jan Marini Skin Research,Inc. (JMSR; http://www.janmarini.com ) today ... Age Intervention Eyelash Conditioner,and Age Intervention Masses of Lashes ... patent infringement lawsuit by Allergan Pharmaceutical as,one reason for ... suspend,these products while we strategically review our options," said ...
... general use, experts caution , , THURSDAY, Jan. 17 (HealthDay News)-- Some ... modifies the body,s immune response. , A study in the Jan. ... no history of heart attacks, as well as those in a ... and of subsequent hospitalizations with such a treatment. , But ...
... a lack of knowledge of health risks posed by ... cell phone technology and use continues to expand and evolve, ... potential health risks associated with long-term exposure to radiofrequency energy. ... women and fetuses -- as well as workers subject to ...
Cached Medicine News:Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2Health News:Former Sufferer of Rare Disease Called Musicogenic Epilepsy Thanks LIJ Medical Team That Ended Her Seizures and Gave Her Back the Gift of Music 2Health News:Jan Marini Skin Research Suspends Sales of Popular Eyelash Products 2Health News:Immune Therapy May Help Some Heart Failure Patients 2Health News:Immune Therapy May Help Some Heart Failure Patients 3Health News:Report Urges More Research Into Cell Phones 2Health News:Report Urges More Research Into Cell Phones 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: